Opinion
Video
Examining FMT for Patients With Recurrent C Difficile infections
Author(s):
Key Takeaways
- Antibiotics can disrupt gut microbiota, leading to potential recurrences of Clostridioides difficile infections (CDI).
- New therapies like fecal microbiota transplantation (FMT) and monoclonal antibodies aim to restore healthy gut flora and provide targeted immune support.
The panelist discusses how fecal microbiota transplantation (FMT) involves transferring stool from healthy donors to restore gut microbiota in patients with recurrent Clostridioides difficile infection, though safety concerns include potential pathogen transmission and careful donor screening requirements, while OpenBiome’s standardized frozen FMT preparations have helped advance accessibility but should be used according to current FDA guidance for investigational use.
Video content above is prompted by the following:
- Describe how FMT works and for which patients this can be used.
- What has recent data shown about the efficacy of FMT in preventing recurrent C difficile?
- What are the safety concerns when using FMT?
- Discuss the recent updates of an investigational FMT therapy from OpenBiome, and how this impacts your clinical decision-making.
Related Videos
Related Content
